Author details

Full Name

Steven T Rosen

Affiliation

ORCID

Career Start Year

1982

Papers

480

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
35338347	SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide.	Cancer Gene Therapy	2023
36307181	<i>APC</i> mosaicism, not always isolated: two first-degree relatives with apparently distinct <i>APC</i> mosaicism.	Gut	2023
36403579	Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.	Lancet Haematology,The	2023
37897709	A phase 1 trial of 8-chloro-adenosine in relapsed/refractory acute myeloid leukemia: An evaluation of safety and pharmacokinetics.		2023
37217248	Intrinsic suppression of type I interferon production underlies the therapeutic efficacy of IL-15-producing natural killer cells in B-cell acute lymphoblastic leukemia.		2023
37470137	Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma.		2023
36895163	Patient-reported functional outcomes and oncological control after primary focal cryotherapy for clinically significant prostate cancer: A Phase II mandatory biopsy-monitored study.	Prostate	2023
36765610	COVID and Cancer: A Complete 3D Advanced Radiological CT-Based Analysis to Predict the Outcome.		2023
37075745	Epigenetic Control of Translation Checkpoint and Tumor Progression via RUVBL1-EEF1A1 Axis.	Adv Sci (Weinh)	2023
37067905	METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL.	Blood Cancer Discov	2023
36697836	Author Correction: The repertoire of mutational signatures in human cancer.	Nature	2023
36798339	<i>MGA</i> deletion leads to Richter's transformation via modulation of mitochondrial OXPHOS.	bioRxiv	2023
36863449	Blockade of the Immune Checkpoint CD47 by TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T-Cell Lymphoma.		2023
36681180	Mechanism of SUMOylation-Mediated Regulation of Type I IFN Expression.		2023
37427589	Reprogramming of PD-1+ M2-like tumor-associated macrophages with anti-PD-L1 and lenalidomide in cutaneous T cell lymphoma.		2023
37541212	TET2-mediated mRNA demethylation regulates leukemia stem cell homing and self-renewal.	Cell Stem Cell	2023
37485873	CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma.		2023
35326597	Synergy of Venetoclax and 8-Chloro-Adenosine in AML: The Interplay of rRNA Inhibition and Fatty Acid Metabolism.	Cancers	2022
35914220	Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma.	Blood	2022
35700381	Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma.	Blood	2022
35743010	Arsenic Trioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 Activation.	International Journal of Molecular Sciences	2022
35554494	Genetic characterization of a missense mutation in the X-linked TAF7L gene identified in an oligozoospermic manâ¿ .	Biology of Reproduction	2022
35788128	Targeting the methionine-methionine adenosyl transferase 2A- S -adenosyl methionine axis for cancer therapy.	Current Opinion in Oncology	2022
36388765	Uncovering novel mutational signatures by <i>de novo</i> extraction with SigProfilerExtractor.	Cell Genom	2022
36115087	Dual targeting fixed duration frontline monoclonal antibody therapy for chronic lymphocytic leukemia: A phase 2 study.	Leukemia Research	2022
36563143	ACTR5 controls CDKN2A and tumor progression in an INO80-independent manner.		2022
35316328	Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE.	Blood	2022
34983615	SUMOylation inhibition enhances dexamethasone sensitivity in multiple myeloma.	Journal of Experimental and Clinical Cancer Research	2022
34977845	Genomic Analysis of Cutaneous CD30-Positive Lymphoproliferative Disorders.		2022
35235473	Emerging drugs for the treatment of cutaneous T-cell lymphoma.	Expert Opinion on Emerging Drugs	2022
34971576	Using Twitter for the identification of COVID-19 vaccine-associated haematological adverse events.	Lancet Haematol	2022
35194801	Expression of immune checkpoint molecules programmed death protein 1, programmed death-ligand 1 and inducible T-cell co-stimulator in mycosis fungoides and SÃ©zary syndrome: association with disease stage and clinical outcome.	British Journal of Dermatology	2022
34774537	MicroRNA Regulation of T-Cell Exhaustion in Cutaneous T Cell Lymphoma.		2022
35134139	Targeting macrophages for enhancing CD47 blockade-elicited lymphoma clearance and overcoming tumor-induced immunosuppression.	Blood	2022
35145225	METTL16 exerts an mA-independent function to facilitate translation and tumorigenesis.	Nature Cell Biology	2022
35013428	Accuracy of mutational signature software on correlated signatures.	Scientific Reports	2022
35058360	Recurrent mutations in topoisomerase IIÎ± cause a previously undescribed mutator phenotype in human cancers.	Proceedings of the National Academy of Sciences of the United States of America	2022
34831008	Identification of a Distinct miRNA Regulatory Network in the Tumor Microenvironment of Transformed Mycosis Fungoides.	Cancers	2021
32296125	Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting.	Leukemia	2021
33753567	Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.	Journal for ImmunoTherapy of Cancer	2021
34239352	Inhibition of <i>de novo</i> pyrimidine synthesis augments Gemcitabine induced growth inhibition in an immunocompetent model of pancreatic cancer.	Int J Biol Sci	2021
33963457	The impact of gender, age, race/ethnicity, and stage on quality of life in a spectrum of cutaneous lymphomas.	Supportive Care in Cancer	2021
33902674	Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine.	Journal of Hematology and Oncology	2021
34280172	Targeting SUMOylation in cancer.	Current Opinion in Oncology	2021
33738338	Oncolytic herpes simplex virus infects myeloma cells <i>inÂ vitro</i> and <i>inÂ vivo</i>.	Mol Ther Oncolytics	2021
34225778	Correction to: Family history assessment significantly enhances delivery of precision medicine in the genomics era.	Genome Med	2021
33465053	CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma.	JCI insight	2021
34210975	High-resolution characterization of gene function using single-cell CRISPR tiling screen.	Nat Commun	2021
33618996	Corrigendum to "Transcription-associated mutation of lasR in Pseudomonas aeruginosa".		2021
34258350	Dupilumab as a therapy option for treatment refractory mogamulizumab-associated rash.	JAAD Case Reports	2021